Cefprozil

Oral
Respiratory tract infections, Skin and skin structure infections

CrCl	Dosage
≤30	Reduce dose by 50%.

May be taken with or without food. May be taken w/ meals to reduce GI discomfort.

Add the amount of water specified on the container in 2 equal portions to provide a susp containing 125 mg or 250 mg per 5 mL. Shake the bottle after each addition.

Hypersensitivity to cefprozil or to other cephalosporins.

History of hypersensitivity to penicillins and GI disease esp colitis. Renal impairment. Pregnancy and lactation.

Diarrhoea, vomiting, abdominal pain, dyspepsia, flatulence, glossitis, mouth pain; rash, serum sickness-like reactions, erythema, exanthema, erythema multiforme, erythema nodosum, Stevens-Johnson syndrome, toxic epidermal necrolysis; dizziness, hyperactivity, headache, nervousness, insomnia, confusion, somnolence; increased AST (SGOT), ALT (SGPT), serum alkaline phosphatase, bilirubin and serum LDH levels; eosinophilia, decreased leukocyte count, agranulocytosis, aplastic anaemia, pancytopenia, haemolytic anaemia, haemorrhage; elevated BUN and serum creatinine, renal dysfunction, toxic nephropathy; vaginitis, genital pruritus, leucorrhoea, vag candidiasis, diaper rash, superinfection. Rarely, urticaria, pruritus, lightheadedness, cholestatic jaundice, neutropenia, thrombocytopenia, thrombocytosis, decreased haematocrit; fever, chills, tinnitus, sweating, visual field defects, angioedema, crying, generalised pain, back pain, leg pain; prolonged partial thromboplastin time, prothrombin time and prothrombin ratio.
Potentially Fatal: Anaphylaxis, pseudomembranous colitis.

PO: B

Monitor renal function and for signs of anaphylaxis during 1st dose.

May enhance the nephrotoxic effect of aminoglycosides. May enhance the anticoagulant effect of vit K antagonists. May diminish the therapeutic effect of BCG, typhoid vaccine and Na picosulfate. May increase serum concentrations w/ probenecid.

Positive direct antiglobulin (Coombs') test results. False-positive result in urine glucose determinations using cupric sulfate (e.g. Benedict's soln, Fehling's soln, Clinitest^®). False-negative result in ferricyanide test for blood glucose.

Description: Cefprozil inhibits bacterial cell wall synthesis by binding to 1 or more of the penicillin-binding proteins (PBPs) which in turn inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Well absorbed from the GI tract. Bioavailability: 90-95%. Time to peak plasma concentration: 1-2 hr.
Distribution: Widely distributed in body tissues. Enters breast milk. Plasma protein binding: Approx 35-45%.
Excretion: Via urine (approx 60%, as unchanged drug). Plasma half-life: 1-1.4 hr.

Source: National Center for Biotechnology Information. PubChem Database. Cefprozil, CID=5281006, https://pubchem.ncbi.nlm.nih.gov/compound/Cefprozil (accessed on Jan. 21, 2020)

Store between 20-25°C. Reconstituted powd for susp: Store between 2-8°C.

Cephalosporins

J01DC10 - cefprozil ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.

Anon. Cefprozil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/10/2014.

Buckingham R (ed). Cefprozil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/10/2014.

Cefprozil Tablet, Film Coated, Powder, for Suspension (DAVA Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/10/2014.

McEvoy GK, Snow EK, Miller J et al (eds). Cefprozil. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 13/10/2014.